CTNNB1 and colorectal carcinoma: JQ1 has been described as an active drug in CRC cell lines and patient-derived xenografts [40], whereas XAV939 is supposed to function via inhibition of Wnt/beta-catenin signaling, which plays a central role in CRC [41].